No Data
No Data
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Amgen Is Maintained at Buy by Argus Research
Amgen Analyst Ratings
Argus Research Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $340
Novo Nordisk, Eli Lilly Still Top 2 Pharma Stocks: Analyst
The Zacks Analyst Blog Highlights Chevron, Amgen, Philip Morris, Hurco and Perma-Pipe